Cardiometabolic risk factors among HIV patients on antiretroviral therapy

Kiage, James N.; Heimburger, Douglas C.; Nyirenda, Christopher K.; Wellons, Melissa F.; Bagchi, Shashwatee; Chi, Benjamin H.; Koethe, John R.; Arnett, Donna K.; Kabagambe, Edmond K.
June 2013
Lipids in Health & Disease;2013, Vol. 12 Issue 1, p1
Academic Journal
Background: HIV and combination antiretroviral therapy (cART) may increase cardiovascular disease (CVD) risk. We assessed the early effects of cART on CVD risk markers in a population with presumed low CVD risk. Methods: Adult patients (n=118) in Lusaka, Zambia were recruited at the time of initiation of cART for HIV/AIDS. Cardiometabolic risk factors were measured before and 90 days after starting cART. Participants were grouped according to cART regimens: Zidovudine + Lamivudine + Nevirapine (n=58); Stavudine + Lamivudine + Nevirapine (n=43); and 'other' (Zidovudine + Lamivudine + Efavirenz, Stavudine + Lamivudine + Efavirenz, Tenofovir + Emtricitabine + Efavirenz or Tenofovir + Emtricitabine + Nevirapine, n=17). ANOVA was used to test whether changes in cardiometabolic risk markers varied by cART regimen. Results: From baseline to 90 days after initiation of cART, the prevalence of low levels of high-density lipoprotein cholesterol (<1.04 mmol/L for men and <1.30 mmol/L for women) significantly decreased (78.8% vs. 34.8%, P<0.001) while elevated total cholesterol (TC ⩾5.18 mmol/L, 5.1% vs. 11.9%, P=0.03) and the homeostasis model assessment of insulin resistance ⩾3.0 (1.7% vs. 17.0%, P<0.001) significantly increased. The prevalence of TC:HDL-c ratio ⩾5.0 significantly decreased (44.9% vs. 6.8%, P<0.001). These changes in cardiometabolic risk markers were independent of the cART regimen. Conclusion: Our results suggest that short-term cART is associated with a cardioprotective lipid profile in Zambia and a tendency towards insulin resistance regardless of the cART regimen.


Related Articles

  • Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study). Santos, J.; Palacios, R.; González, M.; Ruiz, J.; Márquez, M. // International Journal of STD & AIDS;Oct2005, Vol. 16 Issue 10, p677 

    We undertook a transverse study of 603 HIV outpatients to determine their atherogenic lipid profile (ALP) and cardiovascular risk (CVR) factors. CVR was estimated from the Framingham score. ALP was defined as a total cholesterol to high density lipoprotein (HDL)-cholesterol ratio ≥5 plus...

  • A 4-month-old in respiratory distress. MULLAN, PAUL; STEENHOFF, ANDREW; RUTSTEIN, RICHARD // Contemporary Pediatrics;Oct2009, Vol. 26 Issue 10, p26 

    The article describes the case of a 4-month-old infant girl who was diagnosed with HIV. The patient experienced various symptoms, including cough, rapid breathing, jaundice and white stools. The infant was subjected to highly active antiretroviral therapy (HAART) with zidovudine,...

  • Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV-1. Kasirye, P; Kendall, L; Adkison, K K; Tumusiime, C; Ssenyonga, M; Bakeera-Kitaka, S; Nahirya-Ntege, P; Mhute, T; Kekitiinwa, A; Snowden, W; Burger, D M; Gibb, D M; Walker, A S // Clinical Pharmacology & Therapeutics;Feb2012, Vol. 91 Issue 2, p272 

    The bioequivalence of formulations is usually evaluated in healthy adult volunteers. In our study in 19 HIV-1-infected Ugandan children (1.8-4 years of age, weight 12 to <15 kg) receiving zidovudine, lamivudine, and abacavir solutions twice a day for ≥24 weeks, the use of scored tablets...

  • Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-Infected Subjects on Antiretroviral Therapy: The SATURN-HIV Trial. Longenecker, Chris T.; Hileman, Corrilynn O.; Funderburg, Nicholas T.; McComsey, Grace A. // Clinical Infectious Diseases;Oct2014, Vol. 59 Issue 8, p1148 

    In this randomized, placebo-controlled trial, rosuvastatin 10 mg daily improved estimated glomerular filtration rate and reduced plasma cystatin C in HIV-infected patients on antiretroviral therapy. Reductions in cystatin C with statin therapy correlated with reductions in inflammatory...

  • Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. Feinstein, Matthew J. // Heart;8/1/2016, Vol. 102 Issue 15, p1157 

    The author comments on the research that investigates the risk assessment for cardiovascular diseases of HIV patients in the U.S. The topics discussed include the effectiveness of antretroviral therapy (ART) in treating their heart diseases, their risks of developing myocardial infarction (MI),...

  • Antiretroviral Therapy in the Elite Controller: Justified or Premature? Karris, Maile Y.; Haubrich, Richard H. // Journal of Infectious Diseases;6/1/2015, Vol. 211 Issue 11, p1689 

    The author discusses immune system of HIV-positive persons elite controllers who maintain undetectable plasma HIV RNA levels without antiretroviral therapy (ART),and possibility of ART in treating HIV-positive persons. Topics discussed include trial of Strategies for Management of...

  • Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection. Cooper, David A.; Heera, Jayvant; Goodrich, James; Tawadrous, Margaret; Saag, Michael; DeJesus, Edwin; Clumeck, Nathan; Walmsley, Sharon; Ting, Naitee; Coakley, Eoin; Reeves, Jacqueline D.; Reyes-Teran, Gustavo; Westby, Mike; Van Der Ryst, Elna; Ive, Prudence; Mohapi, Lerato; Mingrone, Horacio; Horban, Andrzej; Hackman, Frances; Sullivan, John // Journal of Infectious Diseases;3/15/2010, Vol. 201 Issue 6, p803 

    Background. The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection. Methods. Patients screened for R5 HIV-1 were...

  • ABSTRACTS.  // Advances in Mind-Body Medicine;Spring2004, Vol. 20 Issue 1, p34 

    Presents several abstracts related to trauma and health. "Stable Partnership and Progression to AIDS or Death in HIV Infected Patients Receiving Highly-Active Antiretroviral Therapy: Swiss HIV Cohort Study," by J. Young, S. De Geest and R. Spirig; "Leisure Activities and the Risk of Dementia in...

  • Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naive Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. Gotti, Daria; Cesana, Bruno Mario; Albini, Laura; Calabresi, Alessandra; Izzo, Liaría; Focà, Emanuele; Motta, Davide; Bellagamba, Rita; Fezza, Rita; Narciso, Pasquale; Sighinolfi, Laura; Maggi, Paolo; Brianese, Nigritella; Quiros-Roldan, Eugenia; Guaraldi, Giovanni; Torti, Carlo // HIV Clinical Trials;Sep/Oct2012, Vol. 13 Issue 5, p245 

    Background: Cardiovascular risk in HIV-infected patients is related, at least in part, to serum lipid alterations before and after HAART. Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited. Methods: This was a substudy of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics